Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network

Ähnliche Einträge

• Qualitative Insights into the Factors Impacting Information Sharing in People with Chronic Haematological Malignancies
  von: Debra A. Howell, et al.
  Veröffentlicht: (2024)
• Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia
  von: Fiona Fernando, et al.
  Veröffentlicht: (2025)
• COVID ‐19‐related mortality in a real‐world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK 's Haematological Malignancy Research Network
  von: Alexandra Smith, et al.
  Veröffentlicht: (2025)
• High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition
  von: Daniel James, et al.
  Veröffentlicht: (2024)
• An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies
  von: Akash Joel Sekar, et al.
  Veröffentlicht: (2026)